Coherus Biosciences Announces UDENYCA Divestiture and Revenue Outlook
Express News | Coherus BioSciences Inc - FY 2024 Preliminary Net Revenues Expected to Be $255M-$260M
Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Coherus To Present Randomized Phase 2 Study Evaluating The Combination Of Casdozokitug, Toripalimab And Bevacizumab In Patients With Liver Cancer
Biosimilars Market Industry Trends and Global Forecasts to 2035, Featuring Amgen, BIOCAD, Biocon, Celltrion, Coherus BioSciences, Eli Lilly, Fresenius Kabi, Pfizer, Sandoz and Teva Pharmaceuticals - ResearchAndMarkets.com
TD Cowen Reaffirms Their Buy Rating on Coherus Biosciences (CHRS)
Lnova : they sold their shares?![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Trytosaveabit OP Lnova : That I’m not positive of? I know it says D but the code F states that they were taken using money removed directly from his pay for tax liability So since they have good news coming possibly. I would leave each to make up their minds on it! Hehehe. Hope that makes sense? Hehehe
Trytosaveabit OP Lnova : Also if they are expecting the data to be not so good? Maybe that’s why he said just use some of my shares? Hehehe
Lnova Trytosaveabit OP : Oh I see. Thank you. I hadn’t seen this exact thing on a form before. I appreciate you explaining it to me.
Trytosaveabit OP Lnova : You’re welcome! Yes it can be very confusing at times! Hehehe